2023-505054-17-00招募中4 期
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma
Charite Universitaetsmedizin Berlin KöR37 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2023年7月14日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 136
- 试验地点
- 37
- 主要终点
- Overall survival (OS)
研究概览
简要总结
To compare survival in patients receiving atezolizumab, carboplatin and nab-paclitaxel versus pembrolizumab, platinum and pemetrexed.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Patient has provided written informed consent
- •Adequate hepatic, renal and bone marrow function a) Hemoglobin ≥ 8.0 g/dL b) Absolute neutrophil count ≥ 1.5 x 109/L c) Platelets ≥ 100 x 109/L d) Calculated creatine clearance ≥ 50 mL/min as determined by the Cockgraft-Gault equation and/or creatine ≤ 1,5x upper limit of normal (ULN) e) Serum bilirubin ≤ 1.5 x institutional ULN f) AST/ ALT and alkaline phosphatase ≤ 2.5 x ULN g) International normalized ratio (INR)/ Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PTT is within therapeutic range of intended use of anticoagulants
- •The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
- •Female patients who are considered as woman of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as up to 6 months after the last dose of study treatment. Male patients who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as at least 6 months after the last dose of IMP. Female patients who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile, see section 5.1.5) as well as azoospermic male patients do not require contraception
- •Patient* 18 years or older at time of signing the informed consent form
- •Histologically or cytologically confirmed metastatic stage IV non-squamous NSCLC
- •Negative local testing for TTF-1
- •Negative molecular testing for EGFR mutations and ALK rearrangements (tested locally). Exception: In specific individual cases, treatment can be initiated prior to receiving molecular diagnostics after consulting with the sponsor, if the local principal investigator assesses the likelihood of an EGFR mutation or ALK fusion to be negligible. However, this should only be done in exceptional cases if the patient has particularly high demand for treatment. If it is subsequently found that patients are positive for EGFR mutations and/or ALK rearrangements, they must be withdrawn from the study immediately and must not receive any further study medication. Instead, patients should receive adequate SOC therapy outside the study. Awaiting results for molecular testing remains standard procedure for patient inclusion.
- •PD-L1 tumor proportion score (TPS) < 50%**
- •ECOG performance status ≤ 1
- •Measurable lesions according to RECIST v1.1
- •Life expectancy ≥ 12 weeks
排除标准
- •Mixed histology (small-cell and non-small cell or non-squamous and squamous; patients exhibiting the latter expression pattern may be eligible if the non-squamous part predominates)
- •Active or prior documented autoimmune or inflammatory disorders (including but not limited to diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener’s syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion: a. Patients with vitiligo or alopecia b. Patients with hypothyroidism (e.g., following Hashimoto’s disease) stable on hormone replacement c. Patients with controlled Type I diabetes mellitus on an insulin regimen d. Any chronic skin condition that does not require systemic therapy e. Patients without active disease in the last 5 years may be included but only after consultation with the study physician
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of atezolizumab/pembrolizumab. The following are exceptions to this criterion: a. Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection) b. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent c. Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
- •Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
- •Live vaccine within 30 days prior to first dose of trial treatment
- •Known allergy or contraindication against to or hypersensitivity to any component of the chemotherapy regimen or to atezolizumab or pembrolizumab or any constituents of the products
- •Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study.
- •Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
- •Patients having received: a. Systemic treatment for metastatic or locally advanced disease b. prior PD-1/PD-L1 immunotherapies (prior treatment with CD137 agonists or immune checkpoint blockade therapies, including, but not limited to, anti-cytotoxic T lymphocyte associated protein 4 [anti-CTLA-4], anti T cell immunoreceptor with Ig and tyrosine-based inhibition motif domains [anti-TIGIT], anti-PD-1 and anti-PD-L1 therapeutic antibodies)
- •Symptomatic, neurologically unstable CNS metastases or requiring increasing doses of steroids to manage CNS symptoms within 2 weeks prior to study entry (maximal acceptable dose must be ≤ 10 mg of prednisolone)
- •Leptomeningeal disease
- •History of interstitial lung disease
- •Severe infection within 2 weeks prior to study entry. Clinical signs must have been resolved to CTCAE grade ≤ 1
- •Active infection with hepatitis B or C virus (HBV, HCV), human immunodeficiency virus (HIV) or Mycobacterium tuberculosis
- •Known additional malignancies other than NSCLC, either untreated or having required active treatment within the past 3 years, with the exception of malignancies with a negligible risk of metastasis or death (e.g. 5-year OS rate >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer. Other similar cases can be considered after discussion with the lead investigators
- •Significant cardiovascular disease (≥ NYHA 3)
结局指标
主要结局
Overall survival (OS)
Overall survival (OS)
次要结局
未报告次要终点
研究者
Clinical Trial Project Manager
Scientific
Charite Universitaetsmedizin Berlin KöR
研究点 (37)
Loading locations...
相似试验
招募中
3 期
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"2023-508472-11-00NSABP Foundation Inc.978
招募中
1 期
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinomaCTIS2023-505054-17-00Charite Universitaetsmedizin Berlin KöR136
招募中
2 期
A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer2024-515686-34-00Azienda Ospedaliero Universitaria Di Modena, Azienda Ospedaliero Universitaria Di Modena, Azienda Ospedaliero Universitaria Di Modena53
招募中
3 期
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCNCT07267806Linhui Peng326
招募中
3 期
A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma2024-512015-47-00Incyte Corp.42